Clinical Trials

Main Inclusion Criteria Escalation Part

- Documented CD20+ mature B-cell neoplasm

1. Diffuse large B-cell lymphoma - de novo or transformed

2. High-grade B-cell lymphoma

3. Primary mediastinal large B-cell lymphoma

4. Follicular lymphoma

5. Mantle cell lymphoma

6. Small lymphocytic lymphoma

7. Marginal zone lymphoma (nodal, extranodal or mucosa associated)

- Relapsed, progressive and/or refractory disease following treatment with an anti-CD20
monoclonal antibody (e.g. rituximab) potentially in combination with chemotherapy
and/or relapsed after autologous stem cell rescue.

- ECOG performance status 0,1 or 2

- Patients must have measurable disease by CT, MRI or PET-CT scan

- Acceptable renal function

- Acceptable liver function

Main Inclusion Criteria Expansion Part

- Documented CD20 positive mature B cell neoplasm or CD20+ MCL

- Diffuse large B cell lymphoma, de novo or transformed (including double hit or triple
hit)

- Primary mediastinal large B cell lymphoma

- Follicular lymphoma grade 3B

- Histologic confirmed follicular lymphoma

- Marginal zone lymphomas

- Small lymphocytic lymphoma

- Mantle Cell Lymphoma (prior BTKi or intolerant to BTKi)

- At least 2 therapies including an anti CD20 monoclonal antibody containing
chemotherapy combination regimen

- Either failed prior autologous hematopoietic stem cell transplantation or ineligible
for autologous stem cell transplantation due to age or comorbidities

- At least 1 measurable site of disease based on CT, MRI or PET-CT scan with involvement
of 2 or more clearly demarcated lesions and or nodes

NOTE: Other protocol defined Inclusion criteria may apply.

Eligibility last updated 9/29/22. Questions regarding updates should be directed to the study team contact.